C. Schmidt

发表

Metabolomics takes its place as latest up-and-coming "omic" science.

C. Schmidt, 2004, Journal of the National Cancer Institute.

Costly cancer drugs trigger proposals to modify clinical trial design.

C. Schmidt, 2009, Journal of the National Cancer Institute.

Why do tumors become resistant to antiangiogenesis drugs?

C. Schmidt, 2009, Journal of the National Cancer Institute.

How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.

C. Schmidt, 2011, Journal of the National Cancer Institute.

Komen/ASCO program aims to swell ranks of minority oncologists.

C. Schmidt, 2009, Journal of the National Cancer Institute.

Lack of progress in teen and young adult cancers concerns researchers, prompts study.

C. Schmidt, 2006, Journal of the National Cancer Institute.

Assays that predict outcomes make slow progress toward prime time.

C. Schmidt, 2010, Journal of the National Cancer Institute.

Urine biomarkers may someday detect even distant tumors.

C. Schmidt, 2009, Journal of the National Cancer Institute.

Researchers consider value-of-information theory for selecting trials.

C. Schmidt, 2010, Journal of the National Cancer Institute.

Gleason scoring system faces change and debate.

C. Schmidt, 2009, Journal of the National Cancer Institute.

Mammaprint Reveals Who Can Skip Chemotherapy for Breast Cancer.

C. Schmidt, 2016, Journal of the National Cancer Institute.

Newly revealed genome complexity may mean personalized medicine is farther away.

C. Schmidt, 2007, Journal of the National Cancer Institute.

Third-generation SERMs may face uphill battle.

C. Schmidt, 2010, Journal of the National Cancer Institute.

Latest HapMap update aims to direct researchers to genetic basis of disease.

C. Schmidt, 2005, Journal of the National Cancer Institute.

Fatalism may fuel cancer-causing behaviors.

C. Schmidt, 2007, Journal of the National Cancer Institute.

Testing for carcinogens: shift from animals to automation gathers steam--slowly.

C. Schmidt, 2009, Journal of the National Cancer Institute.

SNPs not living up to promise; experts suggest new approach to disease ID.

C. Schmidt, 2007, Journal of the National Cancer Institute.

The breast cancer chemoprevention debate.

C. Schmidt, 2011, Journal of the National Cancer Institute.

CA-125: a biomarker put to the test.

C. Schmidt, 2011, Journal of the National Cancer Institute.

Abiraterone and MVD3100 take androgen deprivation to a new level.

C. Schmidt, 2011, Journal of the National Cancer Institute.

Cediranib aims for a comeback.

C. Schmidt, 2015, Journal of the National Cancer Institute.

Early detection tools for pancreatic cancer.

C. Schmidt, 2012, Journal of the National Cancer Institute.

Targeted Therapy Makes Inroads in Medulloblastoma.

C. Schmidt, 2015, Journal of the National Cancer Institute.

M. D. Anderson Breaks With IBM Watson, Raising Questions About Artificial Intelligence in Oncology.

Charlie Schmidt, C. Schmidt, 2017, Journal of the National Cancer Institute.

Dose Schedules Inspired by Evolutionary Concepts Lengthen Progression-Free Survival in Mice.

C. Schmidt, 2016, Journal of the National Cancer Institute.

Awaiting a moment of truth for oncolytic viruses.

C. Schmidt, 2013, Journal of the National Cancer Institute.

Immune system's Toll-like receptors have good opportunity for cancer treatment.

C. Schmidt, 2006, Journal of the National Cancer Institute.

Tissue banks trigger worry about ownership issues.

C. Schmidt, 2006, Journal of the National Cancer Institute.

Leroy Hood looks forward to P4 medicine: predictive, personalized, preventive, and participatory.

C. Schmidt, 2014, Journal of the National Cancer Institute.

Experts worry about chilling effect of federal regulations on treating pain.

C. Schmidt, 2005, Journal of the National Cancer Institute.

Lapatinib study supports cancer stem cell hypothesis, encourages industry research.

C. Schmidt, 2008, Journal of the National Cancer Institute.